ROKIT Healthcare has entered the U.S. breast reconstruction market. The company expanded its applications following diabetic foot, skin cancer, and wound regeneration.
The company said on the 20th that it recently applied its technology to a breast reconstruction surgery at a hospital in the Buffalo area in the United States.
Breast reconstruction is surgery performed after mastectomy, and in the United States it is covered by insurance under the Women's Health and Cancer Rights Act (WHCRA). For this reason, it is considered a relatively stable-demand market.
Currently, breast reconstruction uses methods such as implant insertion, autologous tissue transplantation, and cadaveric skin–based assistance. However, implants carry risks of infection and capsular contracture, autologous tissue transplantation imposes surgical burden, and cadaveric skin has expense and other limitations.
A company official said, "ROKIT Healthcare is attempting reconstruction by applying a patient tissue–based ECM (extracellular matrix) technology," and added, "Through this, we are proposing a method to reduce immune responses and the sensation of foreign bodies."
Beyond equipment sales, the business model generates per-surgery charges for consumables and software. In the United States, about 150,000 breast reconstruction surgeries are performed annually.